(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Cell and gene therapy are revolutionary approaches to treating diseases at the molecular level. They involve the manipulation ...

Cell therapies, often described as ‘living therapies’, are transforming cancer treatment. These drugs harness the power of the immune system to deliver remarkable results, particularly for blood ...

With cutting-edge technology, a robust regulatory framework, and a highly skilled team, BTCF is committed to driving innovation in cell therapy research and clinical translation, helping to bring next ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decision ...

Cell and gene therapies (CGTs) represent the cutting edge of drug discovery. 1 These are amongst the most advanced medical treatments, specifically designed to correct the root genetic cause of an ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a ...